Premier Biomedical Files Patent and FDA Application for Ebola Virus Treatment

Phoenix, AZ, January 7, 2015 (Newswire.com) - Premier Biomedical, Inc. (OTCBB: BIEI) announced that they developed an Ebola Virus treatment and filed a related Provisional Patent Application in the fourth quarter of 2014. Premier Biomedical also submitted the Ebola treatment to the Food and Drug Administration (FDA) to outline requirements for investigational testing to determine both safety and efficacy of the technology.

The technology involved in the Ebola Virus treatment utilizes Premier Biomedical's licensed patented method to fight disease-causing molecular compounds outside of the body by "Physically removing the pathophysiologic basis of disease™." As part of the FDA submission, Premier Biomedical provided 3-D CAD models of its proprietaryhardware and is in the process of producing working prototypes.

Premier Biomedical's President & CEO, William A. Hartman, stated that, "This is the first of a number of filings we plan to make with the FDA in short order. We are pleased with their entire response process, and are anxious to get the FDA regulatory process on a number of biomedical devices and treatments behind us, so that we can get our products to the market and relieve suffering as soon as possible."

"We are very excited about our break-through and innovative technology regarding Ebola," said Mitchell S. Felder, M.D., Premier Biomedical's chair of the scientific advisory board.  "Our discussion with the U.S. Food and Drug Administration will further detail the testing requirements to establish safety and efficacy of our proprietary device.  We plan to begin that testing process as soon as possible, so that this very promising technology can be marketed to address this desperate global health need."

About Premier Biomedical, Inc.

Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans, in collaboration with the University of Texas at El Paso and US Department of Defense, initially targeting the treatment of Alzheimer's disease, Traumatic Brain Injury, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX and their business offices are in Western Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI." http://www.premierbiomedicalinc.com/

Safe Harbor Notice

Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

Source: upticknewswire.com